Progressive Supranuclear Palsy (PSP)

Types of PSP
Causes
Common Symptoms
Diagnostic Tests
Non-Pharmacological Treatments
Evidence-Based Pharmacological Treatments
Dietary Molecular Supplements
Advanced/Regenerative Drug Therapies
Surgical and Interventional Procedures
Preventive Strategies
When to See a Doctor
“Do’s” and “Don’ts”
Frequently Asked Questions

Progressive Supranuclear Palsy (PSP), also known as Steele–Richardson–Olszewski syndrome, is a rare, chronic neurodegenerative disorder characterized by gradual deterioration of brain regions that regulate movement, balance, eye motions, swallowing, cognition, and behavior. Over time, abnormal clumps of tau protein accumulate in neurons and glial cells, leading to cell death in the basal ganglia, brainstem, cerebellum, and frontal cerebral cortex. Clinically, PSP presents with early postural instability, unexplained backward falls, slowed vertical eye movements—particularly downward gaze palsy—and a poor or absent response to standard Parkinson’s medications catalog.ninds.nih.govmayoclinic.org.

Progressive Supranuclear Palsy (PSP) is a rare, degenerative brain disorder characterized by the gradual deterioration of specific regions of the brainstem, basal ganglia, and cerebellum. First described in 1964, PSP leads to progressive problems with balance, movement, vision, speech, and cognition. Unlike Parkinson’s disease, PSP patients often exhibit early postural instability and a distinctive difficulty in moving the eyes vertically (supranuclear gaze palsy). Pathologically, PSP is marked by accumulation of abnormal tau protein in neurons and glia, causing neuronal loss and gliosis in brain areas responsible for eye movement control and balance. Symptoms typically begin in the sixth decade of life and progress steadily over several years, resulting in increasing disability and need for multidisciplinary management.

Types of PSP

Neuropathological and clinical heterogeneity in PSP has led to recognition of several subtypes. Each subtype reflects the predominant domains of dysfunction—motor, ocular, cognitive, or mixed:

PSP–Richardson’s Syndrome (PSP-RS)
The classical form. Patients exhibit early, symmetric axial rigidity, frequent backward falls, marked slowing of vertical eye movements (especially downgaze), stiffness of neck extensors, dysphagia, and pseudobulbar affect. Cognitive decline often includes executive dysfunction and emotional lability. PSP-RS typically progresses rapidly, with most patients wheelchair‐dependent within five years en.wikipedia.org.
PSP–Parkinsonism (PSP-P)
Presents initially with asymmetrical limb rigidity, bradykinesia, and mild tremor—features easily mistaken for Parkinson’s disease. Falls and ocular motor impairment occur later and less severely than in PSP-RS. Patients may show transient, modest benefit from levodopa. PSP-P generally follows a somewhat slower progression than PSP-RS en.wikipedia.org.
PSP with Progressive Gait Freezing (PSP-PAGF)
Dominated by early and persistent gait initiation failure or freezing without significant rigidity or tremor. Vertical supranuclear gaze palsy may be minimal or delayed. These patients often present in their mid‐60s and show limited benefit from dopaminergic therapy.
Frontal PSP (PSP-F or PSP-bvFTD)
Characterized by early behavioral changes—apathy, disinhibition, compulsivity—and executive dysfunction resembling behavioral variant frontotemporal dementia (bvFTD). Eye movement abnormalities and parkinsonism emerge later. Mood alterations, irritability, and socially inappropriate behaviors predominate initially sfn.org.
PSP–Corticobasal Syndrome (PSP-CBS)
Exhibits asymmetric limb rigidity, dystonia, apraxia, cortical sensory deficits, and alien limb phenomenon. Vertical gaze palsy and postural instability develop as the disease advances. Pathologically, tau deposition overlaps with corticobasal degeneration.
PSP–Progressive Nonfluent Aphasia (PSP-PNFA)
Early language deficits—nonfluent speech, apraxia of speech, and agrammatism—precede overt ocular motor and postural symptoms. Cognitive and motor features converge over time, fulfilling the criteria for classic PSP.
PSP–Cerebellar Ataxia Variant (PSP-C)
A rare subtype featuring predominant cerebellar signs—limb dysmetria, gait ataxia, dysarthria—alongside typical PSP tau pathology in the cerebellar dentate nucleus. Vertical gaze palsy and falls may be subtle initially.
Vascular PSP (vPSP)
Distinguished by multifocal ischemic lesions superimposed on tauopathy, leading to a PSP-like syndrome in patients with small‐vessel cerebrovascular disease. Presents with mixed vascular and parkinsonian signs and may have uneven progression en.wikipedia.org.

Causes

Although the exact etiology of PSP remains unknown, multiple genetic and environmental factors have been implicated:

MAPT H1 Haplotype
A variant in the tau gene (MAPT) on chromosome 17; individuals with two H1 copies have a substantially increased risk of PSP en.wikipedia.org.
Tau Protein Hyperphosphorylation
Abnormal phosphorylation of tau leads to neurofibrillary tangle formation within neurons and glia, disrupting microtubule stability and axonal transport.
Age
Incidence rises sharply after age 60; cellular resilience and proteostasis mechanisms decline with aging.
Male Sex
PSP slightly predominates in men, suggesting sex‐linked genetic or hormonal influences.
Oxidative Stress
Increased free radical damage contributes to neuronal dysfunction and tau aggregation.
Mitochondrial Dysfunction
Impaired energy production within vulnerable brain regions accelerates neurodegeneration.
Neuroinflammation
Activated microglia and elevated cytokines exacerbate tau pathology and neuronal death.
Vascular Insufficiency
Chronic cerebral hypoperfusion may potentiate PSP pathology, particularly in vascular PSP.
Head Trauma
History of repetitive concussions has been proposed as a catalyst for tauopathies.
Pesticide Exposure
Some epidemiological studies link agricultural chemicals with elevated risk of parkinsonian syndromes.
Heavy Metal Accumulation
Elevated brain or systemic levels of manganese, iron, or lead may promote oxidative damage.
Environmental Toxins
Exposure to industrial solvents and mycotoxins is under investigation as potential triggers.
Chronic Infection
Persistent systemic infections may prime microglial activation and tau misprocessing.
Impaired Proteasome Function
Inefficient degradation of misfolded proteins fosters tau accumulation.
Endoplasmic Reticulum Stress
Disrupted protein folding machinery contributes to neuronal vulnerability.
Lipid Metabolism Abnormalities
Altered cholesterol or sphingolipid turnover may influence tau aggregation.
Genetic Mutations Beyond MAPT
Variants in LRRK2, DCTN1, or other cytoskeletal genes are under active study.
Autoimmune Mechanisms
Autoantibodies against neuronal antigens have been detected in some PSP patients.
Sleep Disturbances
Chronic REM‐sleep behavior disorder and fragmented sleep may accelerate neurodegeneration.
Comorbid Neurodegenerative Pathology
Coexistence of Alzheimer’s or Lewy body pathology can modify PSP onset and progression.

Common Symptoms

PSP manifests with a constellation of motor, ocular, cognitive, and autonomic disturbances:

Postural Instability and Early Falls
Unsteady stance leads to unexplained backward falls within the first two years mayoclinic.org.
Vertical Supranuclear Gaze Palsy
Slowed or absent voluntary eye movements, predominantly downgaze, while reflexive movements may be preserved.
Bradykinesia
Slowness in initiating and executing movements, distinct from Parkinson’s in its symmetry and axial prominence.
Axial Rigidity
Stiffness of neck and trunk extensor muscles results in retrocollis (neck extension) and upright posture.
Dysphagia
Difficulty swallowing due to impaired tongue and pharyngeal muscle coordination, predisposing to aspiration.
Dysarthria
Slurred, hypophonic speech from reduced articulatory precision and respiratory support.
Pseudobulbar Palsy
Emotional lability with uncontrolled laughing or crying episodes.
Gait Freezing
Sudden hesitation when initiating walking, particularly in PSP-PAGF.
Falls During Turning
Instability when pivoting due to axial and postural control deficits.
Impaired Balance
Increased sway and poor corrective responses to perturbations.
Executive Dysfunction
Difficulty planning, multitasking, and shifting mental sets, leading to apathy.
Attention Deficits
Reduced concentration and distractibility.
Memory Impairment
Mild short-term memory loss—less prominent than in Alzheimer’s.
Apathy and Depression
Blunted affect, social withdrawal, and mood disturbances.
Sleep Disturbances
Insomnia, fragmented sleep, and REM‐sleep behavior disorder.
Sialorrhea
Excessive drooling from impaired swallowing.
Blepharospasm
Involuntary eyelid closure causing intermittent vision obstruction.
Neck Dystonia
Involuntary contractions leading to sustained abnormal head posture.
Autonomic Dysfunction
Orthostatic hypotension, urinary urgency or incontinence.
Cognitive Slowing
Generalized slowness in processing information and responding.

Diagnostic Tests

Below are 40 assessments divided into five categories. Each test contributes discrete data toward a PSP diagnosis.

A. Physical Examination

General Neurological Exam
Evaluation of mental status, cranial nerves, motor strength, tone, reflexes, coordination, and gait mayoclinic.org.
Postural Reflex Testing
The “pull test”: sudden backward tug at shoulders to assess recovery steps.
Gait Assessment
Observation of stride length, posture, freezing episodes, and turning stability.
Ocular Motility Screening
Assessment of voluntary saccades (horizontal and vertical) and smooth pursuit movements.
Speech and Swallow Evaluation
Inspection for dysarthria severity and safe swallowing with water or puree.
Limb Coordination
Finger‐to‐nose and heel‐to‐shin tests to detect dysmetria.
Rapid Alternating Movements
Dysdiadochokinesia exam via pronation/supination.
Muscle Tone Assessment
Detection of rigidity, particularly axial rather than limb‐predominant.
Reflex Testing
Deep tendon reflexes for symmetry and hyperreflexia.
Sensory Examination
Light touch, pinprick, and vibration sense to exclude peripheral neuropathy.

B. Manual/Provocative Tests

Pull Test (Extended)
Variations with different tugs to quantify postural response.
Oculocephalic (Doll’s Eye) Reflex
Passive rapid head rotations to distinguish supranuclear from nuclear palsy.
Resistance to Passive Movement
Rating rigidity throughout range of motion.
Grip Strength Dynamometry
Quantitative measure of hand muscle force.
Pronator Drift Test
Detection of subtle upper motor neuron signs.
Limb Resisted Movements
Manual assessment of strength in individual muscle groups.
Vestibulo–Ocular Reflex (Head Impulse Test)
Evaluates brainstem integrity for eye stabilization.
Eyes‐Closed Romberg Test
Differentiates sensory vs. cerebellar ataxia.
Timed Up and Go (TUG) Test
Functional mobility and fall risk quantification.
Functional Reach Test
Measures maximum forward reach without stepping, reflecting balance control.

C. Laboratory and Pathological Tests

Cerebrospinal Fluid (CSF) Tau Protein
Elevated total and phosphorylated tau levels support tauopathy diagnosis en.wikipedia.org.
CSF Neurofilament Light Chain (NfL)
NfL concentrations are 2–5× higher than controls or Parkinson’s patients.
Routine CSF Analysis
Cell count, glucose, protein to exclude inflammatory or infectious etiologies.
Blood Thyroid Function Tests
Rules out thyroid disorders presenting with parkinsonism.
Vitamin B₁₂ and Folate Levels
Excludes nutritional deficiency mimicking neurodegeneration.
Syphilis Serology (RPR/VDRL)
Neurosyphilis can present with movement disorders.
HIV Testing
HIV‐associated neurocognitive disorder may present similarly.
Genetic Testing for MAPT Haplotype
Identification of H1/H1 genotype increases diagnostic confidence.

D. Electrodiagnostic Tests

Electroencephalography (EEG)
Rules out encephalopathy or seizure disorders.
Electromyography (EMG)
Excludes motor neuron disease in patients with rigidity.
Nerve Conduction Studies (NCS)
Detects peripheral neuropathies that may confound diagnosis.
Visual Evoked Potentials (VEPs)
Assesses integrity of visual pathways; may be slowed in brainstem pathology.
Somatosensory Evoked Potentials (SSEPs)
Evaluates dorsal column–medial lemniscal function.
Transcranial Magnetic Stimulation (TMS)
Probes corticospinal excitability and cortical inhibition.

E. Neuroimaging Tests

Magnetic Resonance Imaging (MRI)
Midbrain atrophy with preserved pons (“hummingbird” or “morning glory” sign) is highly suggestive en.wikipedia.org.
Positron Emission Tomography (FDG-PET)
Hypometabolism in midbrain, thalamus, and frontal lobes.
Tau PET Imaging
Direct visualization of tau deposition in basal ganglia and brainstem.
Single-Photon Emission Computed Tomography (SPECT)
Striatal dopaminergic deficits help distinguish PSP from Parkinson’s.
Computed Tomography (CT) Brain
May reveal generalized atrophy, but MRI is preferred for midbrain visualization.
Diffusion Tensor Imaging (DTI)
Quantifies microstructural white matter changes in superior cerebellar peduncles.

Non-Pharmacological Treatments

Non-pharmacological approaches form the cornerstone of PSP management, aiming to maximize function, safety, and quality of life. Below are evidence-based strategies, categorized into physiotherapy/electrotherapy, exercise therapies, mind-body interventions, and educational self-management. Each is detailed with its description, purpose, and mechanism of benefit.

A. Physiotherapy and Electrotherapy Therapies

Balance Training
Description: Guided exercises on wobble boards and foam surfaces.
Purpose: Improve postural stability and reduce fall risk.
Mechanism: Repeated perturbations challenge the vestibular and proprioceptive systems, enhancing neural plasticity in balance pathways.
Gait Reeducation
Description: Therapist-led walking drills focusing on step length and cadence.
Purpose: Normalize walking pattern and prevent shuffling gait.
Mechanism: Repetitive correct stepping patterns reinforce motor cortical networks and spinal central pattern generators.
Cueing Techniques
Description: Use of auditory (metronome) or visual (floor markers) cues.
Purpose: Overcome freezing and improve initiation of movement.
Mechanism: External cues bypass basal ganglia deficits, engaging prefrontal and sensorimotor areas for movement initiation.
Functional Electrical Stimulation (FES)
Description: Low-amplitude electrical pulses applied to leg muscles during walking drills.
Purpose: Enhance muscle activation and prevent foot drop.
Mechanism: Stimulates peripheral nerves to recruit motor units, improving gait symmetry and strength.
Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Surface electrodes deliver mild electrical pulses to painful areas.
Purpose: Relieve musculoskeletal discomfort.
Mechanism: Activates gate-control pathways in the dorsal horn, reducing pain signal transmission.
Rhythmic Auditory Stimulation (RAS)
Description: Walking in synchrony with rhythmic music or metronome beats.
Purpose: Improve gait speed and stride consistency.
Mechanism: Auditory rhythms entrain motor output via cerebellar and cortical coupling.
Vestibular Rehabilitation
Description: Eye-head coordination exercises and habituation drills.
Purpose: Alleviate dizziness and improve gaze stability.
Mechanism: Promotes central compensation for vestibular deficits through cerebellar adaptation.
Postural Correction Sessions
Description: Manual therapy and proprioceptive feedback to align trunk.
Purpose: Reduce kyphosis and enhance upright posture.
Mechanism: Stimulates cervical and thoracic proprioceptors to retrain postural reflexes.
Manual Stretching
Description: Therapist-assisted stretching of neck, trunk, and limbs.
Purpose: Maintain joint range of motion and prevent contractures.
Mechanism: Mechanical elongation of soft tissues increases compliance and reduces spasticity.
Constraint-Induced Movement Therapy (CIMT)
Description: Restricting the less-affected limb to encourage use of the weaker side.
Purpose: Improve upper limb function.
Mechanism: Intensive use-driven neuroplasticity in motor cortex regions controlling the affected limb.
Proprioceptive Neuromuscular Facilitation (PNF)
Description: Diagonal and spiral movement patterns with manual resistance.
Purpose: Enhance neuromuscular control and strength.
Mechanism: Stimulates stretch reflexes and reciprocal inhibition to promote coordinated movement.
Cryotherapy
Description: Application of cold packs to spastic muscles.
Purpose: Reduce muscle tone and discomfort.
Mechanism: Slows nerve conduction velocity and decreases spastic reflexes.
Hydrotherapy
Description: Water-based exercises in a warm pool.
Purpose: Facilitate movement with buoyancy and resistance.
Mechanism: Hydrostatic pressure and warmth reduce tone and support weight-bearing practice.
Robotic Gait Training
Description: Exoskeleton-assisted treadmill walking.
Purpose: Provide intensive, repetitive gait practice.
Mechanism: Robotic assistance ensures consistent stepping patterns, driving motor learning.
Functional Task Practice
Description: Repetitive training of daily activities (e.g., sit-to-stand, reaching).
Purpose: Improve independence in self-care tasks.
Mechanism: Task-specific repetition reinforces cortical and subcortical circuits underpinning functional movements.

B. Exercise Therapies

Progressive Resistance Training
Gradual strengthening of major muscle groups using weights or resistance bands to counteract weakness and improve functional mobility.
Aerobic Conditioning
Low-impact activities such as stationary cycling or brisk walking to enhance cardiovascular health and endurance.
Tai Chi
Slow, flowing movements combined with deep breathing to improve balance, flexibility, and mind-body integration.
Pilates
Core-focused exercises emphasizing alignment, stability, and controlled movements to support trunk strength and posture.
Balance Yoga
Adapted yoga postures emphasizing weight transition, joint alignment, and breathing control to support balance and proprioception.

C. Mind-Body Interventions

Mindfulness Meditation
Guided attention practices to cultivate present-moment awareness, reduce anxiety, and improve emotional regulation.
Cognitive Behavioral Therapy (CBT)
Structured sessions to identify and reframe negative thoughts, improving mood and coping strategies for chronic illness stress.
Relaxation Techniques
Progressive muscle relaxation and guided imagery to lower sympathetic arousal, reducing muscle tension and anxiety.
Biofeedback
Real-time monitoring of physiological signals (e.g., muscle activity) with visual or auditory feedback to teach voluntary control over muscle tension.
Music Therapy
Therapeutic engagement with music to enhance mood, motivation, and motor coordination through rhythmic entrainment.

D. Educational Self-Management

Disease Education Workshops
Structured group sessions covering PSP pathology, symptom management, and caregiver strategies to empower informed self-care.
Home Safety Assessments
Individualized evaluations to identify fall hazards and recommend modifications (e.g., grab bars, non-slip mats).
Assistive Device Training
Instruction in the safe use of walkers, canes, and adaptive utensils to maintain independence in activities of daily living.
Nutrition Counseling
Guidance on swallowing-safe diets, calorie-dense foods, and hydration strategies to prevent malnutrition and aspiration risk.
Caregiver Support Groups
Peer-led meetings providing emotional support, problem-solving skills, and respite resources for family caregivers.

Evidence-Based Pharmacological Treatments

Currently, PSP has no disease-modifying cure, but symptomatic relief can be afforded by various drug classes. Each drug below is described with its typical dosage, pharmacological class, timing, and key side effects.

Levodopa
Class: Dopaminergic agent
Dosage: 300–900 mg/day in divided doses
Timing: TID with meals
Side Effects: Nausea, orthostatic hypotension, dyskinesia
Carbidopa/Levodopa
Class: Dopamine precursor with decarboxylase inhibitor
Dosage: 25/100 mg TID
Timing: 30 minutes before meals
Side Effects: Hallucinations, dry mouth, arrhythmias
Amantadine
Class: NMDA receptor antagonist
Dosage: 100 mg BID
Timing: Morning and early afternoon
Side Effects: Insomnia, peripheral edema, livedo reticularis
Riluzole
Class: Glutamate release inhibitor
Dosage: 50 mg BID
Timing: Morning and evening
Side Effects: Elevated liver enzymes, nausea, weakness
Selegiline
Class: MAO-B inhibitor
Dosage: 5 mg BID
Timing: Morning and early afternoon
Side Effects: Insomnia, dizziness, headache
Baclofen
Class: GABA_B agonist (muscle relaxant)
Dosage: 5 mg TID, titrate up to 80 mg/day
Timing: With meals
Side Effects: Sedation, weakness, hypotension
Tizanidine
Class: α2-adrenergic agonist
Dosage: 2 mg TID, max 36 mg/day
Timing: Every 6–8 hours
Side Effects: Dry mouth, hepatotoxicity, bradycardia
Benzodiazepines (e.g., Clonazepam)
Class: GABA_A agonist
Dosage: 0.25–1 mg at bedtime
Timing: Night
Side Effects: Dependence, drowsiness, cognitive impairment
Botulinum Toxin Type A
Class: Neurotoxin
Dosage: 50–100 units per injection site
Timing: Every 3–4 months
Side Effects: Local weakness, injection pain
Quetiapine
Class: Atypical antipsychotic
Dosage: 25–100 mg at bedtime
Timing: Night
Side Effects: Sedation, metabolic syndrome, hypotension
SSRIs (e.g., Sertraline)
Class: Selective serotonin reuptake inhibitor
Dosage: 50–100 mg daily
Timing: Morning
Side Effects: GI upset, sexual dysfunction
SNRIs (e.g., Venlafaxine)
Class: Serotonin-norepinephrine reuptake inhibitor
Dosage: 37.5–150 mg daily
Timing: Morning
Side Effects: Hypertension, insomnia
Donepezil
Class: Acetylcholinesterase inhibitor
Dosage: 5–10 mg at bedtime
Timing: Night
Side Effects: Diarrhea, muscle cramps
Memantine
Class: NMDA receptor antagonist
Dosage: 5 mg/day, titrate to 20 mg/day
Timing: With morning meals
Side Effects: Dizziness, headache
Modafinil
Class: Wakefulness-promoting agent
Dosage: 100–200 mg in morning
Timing: Morning
Side Effects: Nervousness, insomnia
Propranolol
Class: Beta-blocker
Dosage: 10–40 mg TID
Timing: With meals
Side Effects: Bradycardia, hypotension
Midodrine
Class: α1-agonist
Dosage: 2.5–10 mg TID
Timing: Morning, midday, late afternoon
Side Effects: Supine hypertension, piloerection
Pyridostigmine
Class: Acetylcholinesterase inhibitor
Dosage: 60–120 mg TID
Timing: With meals
Side Effects: Diarrhea, abdominal cramps
Clonidine
Class: α2-agonist
Dosage: 0.1–0.2 mg BID
Timing: Morning and early evening
Side Effects: Dry mouth, sedation
Dextromethorphan/Quinidine
Class: NMDA antagonist/antiarrhythmic
Dosage: 20/10 mg BID
Timing: Morning and evening
Side Effects: Dizziness, nausea

Dietary Molecular Supplements

Coenzyme Q10
Dosage: 300 mg/day
Functional Benefit: Mitochondrial support and antioxidant protection.
Mechanism: Enhances electron transport chain efficiency and scavenges free radicals.
Creatine Monohydrate
Dosage: 5 g/day
Functional Benefit: Improves cellular energy reserves.
Mechanism: Increases phosphocreatine stores, supporting ATP synthesis.
N-Acetylcysteine (NAC)
Dosage: 600–1200 mg BID
Functional Benefit: Glutathione precursor for antioxidant defense.
Mechanism: Elevates intracellular glutathione to reduce oxidative stress.
Alpha-Lipoic Acid
Dosage: 300 mg/day
Functional Benefit: Mitochondrial cofactor and antioxidant.
Mechanism: Regenerates other antioxidants and supports energy metabolism.
Omega-3 Fatty Acids (EPA/DHA)
Dosage: 1–2 g/day
Functional Benefit: Anti-inflammatory and neuroprotective effects.
Mechanism: Modulates membrane fluidity and eicosanoid pathways.
Vitamin D3
Dosage: 2000 IU/day
Functional Benefit: Supports bone health and immune modulation.
Mechanism: Enhances calcium absorption and regulates neuroinflammation.
Vitamin B12
Dosage: 1000 mcg IM monthly or 1000 mcg oral daily
Functional Benefit: Nerve myelination and neurotransmitter synthesis.
Mechanism: Cofactor in methylation reactions and myelin maintenance.
Magnesium L-Threonate
Dosage: 1–2 g/day
Functional Benefit: Cognitive support and neuroplasticity.
Mechanism: Elevates brain magnesium levels, enhancing synaptic function.
Resveratrol
Dosage: 150–500 mg/day
Functional Benefit: Activates sirtuins for cellular resilience.
Mechanism: Stimulates SIRT1 pathways, promoting mitochondrial biogenesis.
Curcumin with Piperine
Dosage: 500 mg curcumin + 5 mg piperine daily
Functional Benefit: Anti-inflammatory and antioxidant activity.
Mechanism: Inhibits NF-κB signaling and scavenges reactive oxygen species.

Advanced/Regenerative Drug Therapies

Alendronate (Bisphosphonate)
Dosage: 70 mg once weekly
Functional: Prevents osteoporosis common in PSP patients.
Mechanism: Inhibits osteoclast-mediated bone resorption.
Zoledronic Acid
Dosage: 5 mg IV annually
Functional: Long-term bone density preservation.
Mechanism: Potent osteoclast apoptosis inducer.
Hyaluronic Acid Viscosupplementation
Dosage: 20 mg intra-articular injection monthly
Functional: Joint lubrication and pain relief.
Mechanism: Restores synovial fluid viscoelasticity.
Nerve Growth Factor (NGF) Injection
Dosage: Experimental – 0.5 mg IT injection monthly
Functional: Promotes neuronal survival.
Mechanism: Binds TrkA receptors to activate pro-survival signaling.
Bone Marrow-Derived MSCs
Dosage: 1×10^6 cells/kg IV infusion quarterly
Functional: Immunomodulation and neuroprotection.
Mechanism: Secrete trophic factors, reduce neuroinflammation.
Adipose-Derived MSCs
Dosage: 1×10^6 cells/kg IV infusion quarterly
Functional: Anti-inflammatory and regenerative effects.
Mechanism: Paracrine signaling to support tissue repair.
Plasma-Derived Exosome Therapy
Dosage: Experimental – 100 µg exosomes IV monthly
Functional: Deliver neuroprotective miRNAs.
Mechanism: Cross blood–brain barrier to modulate gene expression.
Erythropoietin (Neuroprotective Form)
Dosage: 10,000 IU IV weekly
Functional: Reduces neuronal apoptosis.
Mechanism: Activates JAK/STAT pathways promoting cell survival.
GDNF Infusion
Dosage: 100 µg intraputaminal infusion
Functional: Supports dopaminergic neuron health.
Mechanism: Activates RET receptor-mediated trophic signaling.
Stem Cell Mobilizer (G-CSF)
Dosage: 5 µg/kg SC daily for 5 days
Functional: Mobilizes endogenous repair cells.
Mechanism: Stimulates bone marrow progenitor release.

Surgical and Interventional Procedures

Deep Brain Stimulation (Subthalamic Nucleus)
Procedure: Implantation of electrodes in subthalamic nucleus with pulse generator.
Benefits: May modestly improve rigidity and bradykinesia.
Ventriculoperitoneal Shunt
Procedure: Placement of shunt for normal pressure hydrocephalus overlap.
Benefits: Improves gait and urinary symptoms in select cases.
Gastrostomy Tube Placement
Procedure: Percutaneous endoscopic gastrostomy for feeding access.
Benefits: Ensures nutrition and reduces aspiration risk.
Tendon Lengthening Surgeries
Procedure: Surgical release of spastic tendons (e.g., Achilles).
Benefits: Improves joint range and reduces contractures.
Selective Dorsal Rhizotomy
Procedure: Microsurgical sectioning of sensory nerve roots in spine.
Benefits: Reduces lower-limb spasticity.
Botulinum Toxin Injections (EMG-Guided)
Procedure: Targeted injection into spastic muscles under EMG.
Benefits: Reduces focal spasticity and pain.
Pallidotomy
Procedure: Stereotactic lesion of globus pallidus interna.
Benefits: May improve rigidity and dyskinesia.
Stem Cell Transplantation (Experimental)
Procedure: Intracerebral injection of neural stem cells.
Benefits: Potential neuroregeneration in affected areas.
Spinal Cord Stimulator Implant
Procedure: Epidural electrode placement to modulate spinal circuits.
Benefits: May alleviate refractory spasticity and pain.
Respiratory Diaphragmatic Pacing
Procedure: Phrenic nerve stimulator implantation.
Benefits: Supports breathing in advanced respiratory muscle weakness.

Preventive Strategies

Head Injury Prevention: Wear protective headgear and take fall-prevention measures.
Cardiovascular Health: Control hypertension, diabetes, and hyperlipidemia.
Regular Physical Activity: Maintain strength and balance through ongoing exercise.
Bone Health Optimization: Ensure adequate calcium and vitamin D intake.
Smoking Cessation: Reduces oxidative stress and vascular damage.
Moderate Alcohol Use: Avoid excessive consumption.
Social Engagement: Stimulates cognition and mood stability.
Mental Stimulation: Engage in puzzles, reading, and learning new skills.
Healthy Sleep Hygiene: Supports brain repair and overall health.
Nutrient-Rich Diet: Emphasize antioxidants, omega-3s, and lean proteins.

When to See a Doctor

Seek prompt medical evaluation if you experience:

Sudden worsening of balance leading to frequent falls
New-onset swallowing difficulty or choking episodes
Rapid changes in speech clarity or volume
Noticeable vision problems, especially difficulty looking up or down
Sudden mood changes, depression, or cognitive decline

Early consultation ensures timely intervention and support.

“Do’s” and “Don’ts”

Do:

Practice daily balance exercises.
Use assistive devices consistently.
Eat small, frequent meals to prevent choking.
Prioritize sleep and rest.
Stay socially connected.
Monitor bone density and take supplements.
Attend regular physical therapy sessions.
Keep emergency contact information accessible.
Practice relaxation techniques.
Educate caregivers on safety measures.

Don’t:

Ignore new swallowing or voice changes.
Attempt complex movements without support.
Overexert and risk falls.
Skip medication or therapy appointments.
Live in cluttered environments.
Smoke or use excessive alcohol.
Neglect mental health.
Eat hard or slippery foods without modification.
Delay reporting new symptoms.
Isolate — maintain community and family ties.

Frequently Asked Questions

What causes PSP?
The exact cause is unknown, but abnormal accumulation of tau protein leads to neuronal death in areas controlling eye movement and balance.
Is PSP hereditary?
Most cases are sporadic, but rare familial forms linked to tau gene mutations exist.
How fast does PSP progress?
Symptoms typically worsen over 5–10 years from onset.
Can PSP be cured?
There is no cure; treatment focuses on symptom management and supportive care.
Will levodopa help?
Some patients have modest improvement in rigidity and bradykinesia with levodopa-based regimens.
Is physical therapy beneficial?
Yes—regular physiotherapy can slow functional decline and reduce fall risk.
What vision changes occur?
Early difficulty with vertical gaze, especially looking down, leading to impaired reading and step negotiation.
When should I consider a feeding tube?
If you have recurrent aspiration or unintentional weight loss despite dietary modifications.
Can speech therapy help?
Absolutely—voice and swallowing exercises can maintain communication and reduce choking.
Are there clinical trials?
Yes; trials of tau-targeting agents, stem cell therapies, and neuroprotective drugs are ongoing.
How do I prevent falls?
Use assistive devices, practice balance exercises, and modify home hazards.
What mental health support is available?
Counseling, support groups, and antidepressant medications can address depression and anxiety.
Should I take supplements?
Antioxidants like CoQ10 and omega-3s may offer neuroprotective benefits, but discuss with your doctor.
Is deep brain stimulation an option?
It’s experimental in PSP and may yield only limited benefit compared to Parkinson’s disease.
How can caregivers help?
Educate on safe transfers, communication strategies, medication schedules, and emotional support.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: June 30, 2025.

PDF Document For This Disease Conditions

References

SaveSavedRemoved 0